12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VTX-2337: Phase II started

VentiRx began the double-blind, placebo-controlled, U.S. Phase II ACTIVE8 trial to compare 3 mg/m 2 IV VTX-2337 plus standard of care (SOC: 5-FU and cetuximab plus cisplatin or carboplatin) vs. SOC alone in 175 patients with recurrent or metastatic SCCHN. Patients...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >